A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
NCT ID: NCT00338273
Last Updated: 2013-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2006-12-31
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
NCT00080314
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
NCT00094432
Study of Aripiprazole in Patients With a History of Bipolar Disorder
NCT00036348
Study of Aripiprazole in Patients With Bipolar I Disorder
NCT00257972
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
NCT00036101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1
Aripiprazole
Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
A2
Placebo
Tablets, Oral, 0 mg, Once daily, 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aripiprazole
Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
Placebo
Tablets, Oral, 0 mg, Once daily, 8 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must sign informed consent prior to protocol-related procedures
Exclusion Criteria
* Significant risk of committing suicide
* Any serious unstable medical conditions
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka America Pharmaceutical
INDUSTRY
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Durham, North Carolina, United States
Local Institution
Ahmedabad, Gujarat, India
Local Institution
Chennai, , India
Local Institution
Delhi, , India
Local Institution
Hyderabad, , India
Local Institution
Lucknow, , India
Local Institution
Mumbai, , India
Local Institution
Visakhapatnam, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN138-149
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.